替吉奥联合奥沙利铂治疗晚期食管癌近期疗效观察

目的 观察替吉奥联合奥沙利铂治疗晚期食管癌的近期疗效及不良反应.方法 30例晚期食管癌均接受化疗,替吉奥80mg/(m2 ·d),分2次,餐后口服,dl-14;奥沙利铂130 mg/m2,dl,静脉滴注＞3小时,21天为1周期,2周期后行胸腹部CT及消化道钡餐造影或胃镜评价疗效,并评价不良反应.结果 30例患者均可评价疗效,完全缓解(CR)0例,部分缓解(PR) 12例,病情稳定(SD)8例,病情进展(PD) 10例,有效率(CR+ PR)为40.0％,临床获益率(CR+PR+SD)为66.7％.中位疾病进展时间5月,1年生存率63.3％.主要不良反应为血液学毒性、消化道反应、肝功能损伤、皮疹、神经毒性等.结论 替吉奥联合奥沙利铂治疗晚期食管癌疗效较好,不良反应可耐受.

S-1 capsule combined with oxaliplatin for patients with advanced esophageal cancer

Objective To evaluate the efficacy and toxicity of S-1 capsule（ tegafur-gimeracil-oteracil） combined with oxaliplatin in treatment of advanced esophageal cancer. Methods Thirty patients with advanced esophageal cancer received S-1 plus oxaliplatin chemotherapy regimen： S-1 capsule 80 mg/（ m2·d）,bid,d1-14; oxaliplatin 130 mg/m2,d1,i. v.〉 3 h; 21 d as one cycle. After two cycles of chemotherapy,the efficacy and toxicity were evaluated. Results All30 cases were evaluable. Overall response rate was 40. 0%,disease control rate was 66. 7%,the median time to progression was 5 months and one-year survival rate was 63. 3%. The major toxicities were hemotological toxicity,gastrointestinal reactions,liver dysfunction,rash and neurotoxicity. Conclusion S-1 capsule combined with oxaliplatin is effective and safe for patients with advanced esophageal cancer.